Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 23.14% higher on its value in year-to-date trading and has touched a low of $1.36 and a high of $3.62 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CKPT stock was last observed hovering at around $2.64 in the last trading session, with the day’s gains setting it 0.18%.
Currently trading at $2.82, the stock is 19.59% and 22.83% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.2 million and changing 6.82% at the moment leaves the stock 37.47% off its SMA200. CKPT registered 43.15% gain for a year compared to 6-month gain of 68.86%. The firm has a 50-day simple moving average (SMA 50) of $2.2843 and a 200-day simple moving average (SMA200) of $2.0487.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.90% loss in the last 1 month and extending the period to 3 months gives it a 9.51%, and is 20.51% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.48% over the week and 6.63% over the month.
Checkpoint Therapeutics Inc (CKPT) has around 23 employees, a market worth around $126.96M and $0.08M in sales. Profit margin for the company is -54444.87%. Distance from 52-week low is 107.35% and -22.10% from its 52-week high.
Checkpoint Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.15 with sales reaching $10k over the same period.The EPS is expected to grow by 75.29% this year, but quarterly earnings will post -70.90% year-over-year. Quarterly sales are estimated to shrink -67.70% in year-over-year returns.
49.0 institutions hold shares in Checkpoint Therapeutics Inc (CKPT), with institutional investors hold 15.92% of the company’s shares. The shares outstanding are 45.02M, and float is at 37.36M with Short Float at 11.71%. Institutions hold 13.45% of the Float.
Checkpoint Therapeutics Inc (CKPT) Insider Activity
The most recent transaction is an insider sale by Oliviero James F III, the company’s CEO, President and Director. SEC filings show that Oliviero James F III sold 24,610 shares of the company’s common stock on Jun 26 ’24 at a price of $2.05 per share for a total of $50450.0. Following the sale, the insider now owns 1.98 million shares.
Checkpoint Therapeutics Inc disclosed in a document filed with the SEC on Jun 26 ’24 that GRAY WILLIAM GARRETT (Chief Financial Officer) sold a total of 13,038 shares of the company’s common stock. The trade occurred on Jun 26 ’24 and was made at $2.06 per share for $26858.0. Following the transaction, the insider now directly holds 0.67 million shares of the CKPT stock.
Still, SEC filings show that on Feb 28 ’24, Oliviero James F III (CEO, President and Director) disposed off 5,894 shares at an average price of $2.06 for $12142.0. The insider now directly holds 350,836 shares of Checkpoint Therapeutics Inc (CKPT).
